The objective of this study is to confirm the safety of ATGAM in patients with moderate to severe aplastic anemia under the actual use in Japan. The registration criteria is patients with moderate to severe aplastic anemia who receive ATGAM. The observation period is 24 weeks (6 months) from the start of administration (Day 1). However, in cases where treatment has been completed or discontinued less than 24 weeks after the start of administration, observation is continued until completion (discontinuation) of treatment.
Study Type
OBSERVATIONAL
Enrollment
1
Usually, 40 mg of anti-human thymocyte immunoglobulin, equine per kilogram of body weight should be slowly administered by intravenous drip infusion once daily. The duration of treatment should be 4 days.
Pfizer
Tokyo, Japan
Number of participants with adverse drug reactions (ADRs)
Time frame: 24 weeks (6 months) from the start of administration (Day 1)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.